Member Login
Logout
Voyager Toolkit
Become a Voyager

All Articles

An ADC That Kills Old Cells, Not Cancer Cells

StarkAge Therapeutics is bringing a senolytic ADC targeting DPP4/CD26 to AACR 2026, aiming to clear senescent cells in the tumor microenvironment.

Antifungals Are Boring. They’re Also About to Save a Lot of Lives.

Elion Therapeutics started a Phase 2 trial of turletricin, a next-generation polyene antifungal designed to keep amphotericin's power without the kidney toxicity.

Daiichi Wants Better Delivery. They Just Bet on a Nano Motor.

Interna Therapeutics signed a research collaboration with Daiichi Sankyo to evaluate its Molecular Nano Motor delivery platform for targeted therapeutics.

A “Mirror-Image” RNA Drug Just Got Glioblastoma Data Into Nature

TME Pharma published GLORIA trial data in Nature Communications showing NOX-A12 plus radiation and bevacizumab improved survival in MGMT-unmethylated GBM.

Janux Has Three PSMA Drugs Now. The Backup Just Got Its First Patient.

Janux Therapeutics dosed the first patient in JANX014, a double-masked PSMA T cell engager that backs up its lead JANX007 in mCRPC.

A 488-Amino-Acid CRISPR That Fits Inside an AAV

Metagenomi published a compact Cas12f CRISPR variant small enough for single-AAV delivery, with editing activity that rivals larger systems.

A Chinese Biotech Just Filed the World’s First LILRB4 T Cell Engager

Mabwell's 6MW5311 became the first LILRB4/CD3 bispecific T cell engager to reach clinical submission anywhere in the world.

67% in Ovarian. 50% in Prostate. Without the Bone Marrow Beating.

Acerand Therapeutics drops Phase I/II data for ACE-106, a PARP1-selective inhibitor with response rates that put it in best-in-class territory.

Mesoblast Puts a CAR on a Stem Cell

Mesoblast licenses Mayo Clinic CAR technology to build CAR-MSC therapies for autoimmune disease.

An EP300/CBP Inhibitor Designed to Clear Before It Hurts

Opna Bio's OPN-6602, an oral EP300/CBP dual inhibitor, receives FDA Fast Track for relapsed myeloma.

RNA-Targeting Small Molecules Pass Their First Pharma Test

Wayfinder Biosciences advances Daiichi Sankyo collaboration on RNA-targeting small molecules to lead optimization.

A Dual-Pathway Peptide for the Pain Chemo Leaves Behind

Dogwood Therapeutics gets FDA IND acceptance for SP16 in chemotherapy-induced pain, funded by NCI.

Janux Has Three PSMA Drugs Now. The Backup Just Got Its First Patient.

Janux Therapeutics dosed the first patient in JANX014, a double-masked PSMA T cell engager that backs up its lead JANX007 in mCRPC.

A 488-Amino-Acid CRISPR That Fits Inside an AAV

Metagenomi published a compact Cas12f CRISPR variant small enough for single-AAV delivery, with editing activity that rivals larger systems.

A Chinese Biotech Just Filed the World’s First LILRB4 T Cell Engager

Mabwell's 6MW5311 became the first LILRB4/CD3 bispecific T cell engager to reach clinical submission anywhere in the world.

67% in Ovarian. 50% in Prostate. Without the Bone Marrow Beating.

Acerand Therapeutics drops Phase I/II data for ACE-106, a PARP1-selective inhibitor with response rates that put it in best-in-class territory.

20 Minutes to Burn a Pancreatic Tumor

Sonire Therapeutics closes $18M Series A for focused ultrasound ablation in pancreatic cancer.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

FDA Breakthrough for a Urine-Based Cancer Test

TOBY Inc receives FDA Breakthrough Device Designation for a urine-based multi-cancer early detection test.

99% B-Cell Depletion From an Antibody, Not CAR-T

Hinge Bio doses first patient with HB2198, a multispecific antibody targeting CD19 and CD20 for autoimmune disease.

Pancreatic Cancer Finally Has a Weak Spot. Here’s Who’s Going After It.

Revolution Medicines' Phase 3 daraxonrasib data validates a growing wave of early-stage companies attacking RAS.

The Push To Unlock Brain Cancer Is Heating Up. Time To Pay Attention.

In five weeks, 16 companies made moves against brain cancer. Gene therapies, oral pills, oncolytics, sonodynamic therapy. Something shifted.

Vivatides Raises $54M to Escape the Liver

Vivatides Therapeutics closes an oversubscribed $54M Series A for its extrahepatic RNA delivery platform.

Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

Novo Nordisk Called OpenAI. So Did Everyone Else.

Novo Nordisk partners with OpenAI as AI drug discovery deal flow surpasses $5B in five months.

One Bought a Podcast. The Other Bought a Lab.

Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.

$787 Million Says AI Can Design Better Biologics Than You

An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.

Teaching a Gene Editor to Optimize Itself

Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.

Molecular Glues Were Discovered by Accident. Not Anymore.

Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.

220 Targets. Zero Antibodies. One AI Platform.

One-third of all FDA-approved drugs target GPCRs, but almost no antibodies do. Antiverse's AI platform is changing that — and the CF Foundation just signed on.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

“Cue” The Music. $7.5M for Picking the Right Molecule.

Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.

An Oral Pill for Glioblastoma. From Oslo.

Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.

One Patient. One B Cell. A Whole New Playbook.

Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.

Edit the RNA. Keep the DNA. Fix the Disease.

AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.

ADCs Hit a Wall. This Company Brought a Different Weapon.

ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.

Your Knee Called. It Wants New Cartilage.

Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.

No Drugs. Just Ultrasound.

SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.

Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy

NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.

Alltrna Sends the First tRNA Therapeutic Into Human Testing

Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.
Home
Login
Logout
Become a Voyager
All
Emerging Modalities
AI In Biotech
Landscape Reports
Advanced Search
Podcast
Featured Companies
About Us
Useful links
Privacy Policy
Terms of Use

Voyager Toolkit

Advanced Signal Search
Landscape Reports
More coming soon...